TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Biogeneric Drugs Market, Global Outlook and Forecast 2023-2030

Biogeneric Drugs Market, Global Outlook and Forecast 2023-2030

  • Category:Life Sciences
  • Published on : 25 December 2022
  • Pages :94
  • Formats:
  • Report Code:SMR-7519367
OfferClick for best price

Best Price: $2320

Biogeneric Drugs Market Size, Share 2022


Market Analysis and Insights: Global Biogeneric Drugs Market

The global Biogeneric Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biogeneric Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biogeneric Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biogeneric Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biogeneric Drugs market.

Global Biogeneric Drugs Scope and Market Size

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Insulins

Growth Hormones

Monoclonal Antibodies

Others

Segment by Application

Hospital

Clinics

Research Centers

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

By Company

Sandoz International

Teva pharmaceutical industries

Mylan

3SBio

Shanghai Fosun Pharmaceutical

Tonghua Dongbao Pharmaceutical

Biocon

Reliance life sciences

Probiomed

Biosidus

AMEGA Biotech

Celltrion

LG life Science

Dong-A Pharmaceutical

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Biogeneric Drugs product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Biogeneric Drugs, with price, sales, revenue, and global market share of Biogeneric Drugs from 2019 to 2022.

Chapter 3, the Biogeneric Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Biogeneric Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Biogeneric Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Biogeneric Drugs.

Chapter 13, 14, and 15, to describe Biogeneric Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Biogeneric Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Biogeneric Drugs Market, Global Outlook and Forecast 2023-2030
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 94 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Biogeneric Drugs Market Overview
1.1 Product Overview and Scope of Biogeneric Drugs
1.2 Biogeneric Drugs Segment by Type
1.2.1 Global Biogeneric Drugs Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Insulins
1.2.3 Growth Hormones
1.2.4 Monoclonal Antibodies
1.2.5 Others
1.3 Biogeneric Drugs Segment by Application
1.3.1 Global Biogeneric Drugs Sales Comparison by Application: (2023-2030)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Research Centers
1.4 Global Biogeneric Drugs Market Size Estimates and Forecasts
1.4.1 Global Biogeneric Drugs Revenue 2018-2030
1.4.2 Global Biogeneric Drugs Sales 2018-2030
1.4.3 Biogeneric Drugs Market Size by Region: 2018 Versus 2022 Versus 2030
2 Biogeneric Drugs Market Competition by Manufacturers
2.1 Global Biogeneric Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Biogeneric Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Biogeneric Drugs Average Price by Manufacturers (2018-2023)
2.4 Manufacturers Biogeneric Drugs Manufacturing Sites, Area Served, Product Type
2.5 Biogeneric Drugs Market Competitive Situation and Trends
2.5.1 Biogeneric Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biogeneric Drugs Players Market Share by Revenue
2.5.3 Global Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biogeneric Drugs Retrospective Market Scenario by Region
3.1 Global Biogeneric Drugs Retrospective Market Scenario in Sales by Region: 2018-2023
3.2 Global Biogeneric Drugs Retrospective Market Scenario in Revenue by Region: 2018-2023
3.3 North America Biogeneric Drugs Market Facts & Figures by Country
3.3.1 North America Biogeneric Drugs Sales by Country
3.3.2 North America Biogeneric Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Biogeneric Drugs Market Facts & Figures by Country
3.4.1 Europe Biogeneric Drugs Sales by Country
3.4.2 Europe Biogeneric Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biogeneric Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Biogeneric Drugs Sales by Region
3.5.2 Asia Pacific Biogeneric Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Biogeneric Drugs Market Facts & Figures by Country
3.6.1 Latin America Biogeneric Drugs Sales by Country
3.6.2 Latin America Biogeneric Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Biogeneric Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Biogeneric Drugs Sales by Country
3.7.2 Middle East and Africa Biogeneric Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Biogeneric Drugs Historic Market Analysis by Type
4.1 Global Biogeneric Drugs Sales Market Share by Type (2018-2023)
4.2 Global Biogeneric Drugs Revenue Market Share by Type (2018-2023)
4.3 Global Biogeneric Drugs Price by Type (2018-2023)
5 Global Biogeneric Drugs Historic Market Analysis by Application
5.1 Global Biogeneric Drugs Sales Market Share by Application (2018-2023)
5.2 Global Biogeneric Drugs Revenue Market Share by Application (2018-2023)
5.3 Global Biogeneric Drugs Price by Application (2018-2023)
6 Key Companies Profiled
6.1 Sandoz International
6.1.1 Sandoz International Corporation Information
6.1.2 Sandoz International Description and Business Overview
6.1.3 Sandoz International Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Sandoz International Biogeneric Drugs Product Portfolio
6.1.5 Sandoz International Recent Developments/Updates
6.2 Teva pharmaceutical industries
6.2.1 Teva pharmaceutical industries Corporation Information
6.2.2 Teva pharmaceutical industries Description and Business Overview
6.2.3 Teva pharmaceutical industries Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva pharmaceutical industries Biogeneric Drugs Product Portfolio
6.2.5 Teva pharmaceutical industries Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Corporation Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Mylan Biogeneric Drugs Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 3SBio
6.4.1 3SBio Corporation Information
6.4.2 3SBio Description and Business Overview
6.4.3 3SBio Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 3SBio Biogeneric Drugs Product Portfolio
6.4.5 3SBio Recent Developments/Updates
6.5 Shanghai Fosun Pharmaceutical
6.5.1 Shanghai Fosun Pharmaceutical Corporation Information
6.5.2 Shanghai Fosun Pharmaceutical Description and Business Overview
6.5.3 Shanghai Fosun Pharmaceutical Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Portfolio
6.5.5 Shanghai Fosun Pharmaceutical Recent Developments/Updates
6.6 Tonghua Dongbao Pharmaceutical
6.6.1 Tonghua Dongbao Pharmaceutical Corporation Information
6.6.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.6.3 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Portfolio
6.6.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
6.7 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biocon Biogeneric Drugs Product Portfolio
6.7.5 Biocon Recent Developments/Updates
6.8 Reliance life sciences
6.8.1 Reliance life sciences Corporation Information
6.8.2 Reliance life sciences Description and Business Overview
6.8.3 Reliance life sciences Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Reliance life sciences Biogeneric Drugs Product Portfolio
6.8.5 Reliance life sciences Recent Developments/Updates
6.9 Probiomed
6.9.1 Probiomed Corporation Information
6.9.2 Probiomed Description and Business Overview
6.9.3 Probiomed Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Probiomed Biogeneric Drugs Product Portfolio
6.9.5 Probiomed Recent Developments/Updates
6.10 Biosidus
6.10.1 Biosidus Corporation Information
6.10.2 Biosidus Description and Business Overview
6.10.3 Biosidus Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Biosidus Biogeneric Drugs Product Portfolio
6.10.5 Biosidus Recent Developments/Updates
6.11 AMEGA Biotech
6.11.1 AMEGA Biotech Corporation Information
6.11.2 AMEGA Biotech Biogeneric Drugs Description and Business Overview
6.11.3 AMEGA Biotech Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 AMEGA Biotech Biogeneric Drugs Product Portfolio
6.11.5 AMEGA Biotech Recent Developments/Updates
6.12 Celltrion
6.12.1 Celltrion Corporation Information
6.12.2 Celltrion Biogeneric Drugs Description and Business Overview
6.12.3 Celltrion Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Celltrion Biogeneric Drugs Product Portfolio
6.12.5 Celltrion Recent Developments/Updates
6.13 LG life Science
6.13.1 LG life Science Corporation Information
6.13.2 LG life Science Biogeneric Drugs Description and Business Overview
6.13.3 LG life Science Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 LG life Science Biogeneric Drugs Product Portfolio
6.13.5 LG life Science Recent Developments/Updates
6.14 Dong-A Pharmaceutical
6.14.1 Dong-A Pharmaceutical Corporation Information
6.14.2 Dong-A Pharmaceutical Biogeneric Drugs Description and Business Overview
6.14.3 Dong-A Pharmaceutical Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Dong-A Pharmaceutical Biogeneric Drugs Product Portfolio
6.14.5 Dong-A Pharmaceutical Recent Developments/Updates
7 Biogeneric Drugs Manufacturing Cost Analysis
7.1 Biogeneric Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biogeneric Drugs
7.4 Biogeneric Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biogeneric Drugs Distributors List
8.3 Biogeneric Drugs Customers
9 Biogeneric Drugs Market Dynamics
9.1 Biogeneric Drugs Industry Trends
9.2 Biogeneric Drugs Market Drivers
9.3 Biogeneric Drugs Market Challenges
9.4 Biogeneric Drugs Market Restraints
10 Global Market Forecast
10.1 Biogeneric Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biogeneric Drugs by Type (2023-2030)
10.1.2 Global Forecasted Revenue of Biogeneric Drugs by Type (2023-2030)
10.2 Biogeneric Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biogeneric Drugs by Application (2023-2030)
10.2.2 Global Forecasted Revenue of Biogeneric Drugs by Application (2023-2030)
10.3 Biogeneric Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biogeneric Drugs by Region (2023-2030)
10.3.2 Global Forecasted Revenue of Biogeneric Drugs by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Biogeneric Drugs Sales Growth Rate Comparison by Type (2023-2030) & (K Units) & (US$ Million)
Table 2. Global Biogeneric Drugs Sales Growth Rate Comparison by Application (2023-2030) & (K Units) & (US$ Million)
Table 3. Global Biogeneric Drugs Market Size by Region (US$ Million) (2018 VS 2022 VS 2030)
Table 4. Global Biogeneric Drugs Market Competitive Situation by Manufacturers in 2022
Table 5. Global Biogeneric Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 6. Global Biogeneric Drugs Sales Market Share by Manufacturers (2018-2023)
Table 7. Global Biogeneric Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 8. Global Biogeneric Drugs Revenue Share by Manufacturers (2018-2023)
Table 9. Global Market Biogeneric Drugs Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 10. Manufacturers Biogeneric Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Biogeneric Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Biogeneric Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biogeneric Drugs as of 2022)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Biogeneric Drugs Sales by Region (2018-2023) & (K Units)
Table 16. Global Biogeneric Drugs Sales Market Share by Region (2018-2023)
Table 17. Global Biogeneric Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 18. Global Biogeneric Drugs Revenue Market Share by Region (2018-2023)
Table 19. North America Biogeneric Drugs Sales by Country (2018-2023) & (K Units)
Table 20. North America Biogeneric Drugs Sales Market Share by Country (2018-2023)
Table 21. North America Biogeneric Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 22. North America Biogeneric Drugs Revenue Market Share by Country (2018-2023)
Table 23. Europe Biogeneric Drugs Sales by Country (2018-2023) & (K Units)
Table 24. Europe Biogeneric Drugs Sales Market Share by Country (2018-2023)
Table 25. Europe Biogeneric Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 26. Europe Biogeneric Drugs Revenue Market Share by Country (2018-2023)
Table 27. Asia Pacific Biogeneric Drugs Sales by Region (2018-2023) & (K Units)
Table 28. Asia Pacific Biogeneric Drugs Sales Market Share by Region (2018-2023)
Table 29. Asia Pacific Biogeneric Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 30. Asia Pacific Biogeneric Drugs Revenue Market Share by Region (2018-2023)
Table 31. Latin America Biogeneric Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Latin America Biogeneric Drugs Sales Market Share by Country (2018-2023)
Table 33. Latin America Biogeneric Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Latin America Biogeneric Drugs Revenue Market Share by Country (2018-2023)
Table 35. Middle East and Africa Biogeneric Drugs Sales by Country (2018-2023) & (K Units)
Table 36. Middle East and Africa Biogeneric Drugs Sales Market Share by Country (2018-2023)
Table 37. Middle East and Africa Biogeneric Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 38. Middle East and Africa Biogeneric Drugs Revenue Market Share by Country (2018-2023)
Table 39. Global Biogeneric Drugs Sales by Type (2018-2023) & (K Units)
Table 40. Global Biogeneric Drugs Sales Market Share by Type (2018-2023)
Table 41. Global Biogeneric Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 42. Global Biogeneric Drugs Revenue Share by Type (2018-2023)
Table 43. Global Biogeneric Drugs Price by Type (2018-2023) & (USD/Unit)
Table 44. Global Biogeneric Drugs Sales (K Units) by Application (2018-2023)
Table 45. Global Biogeneric Drugs Sales Market Share by Application (2018-2023)
Table 46. Global Biogeneric Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 47. Global Biogeneric Drugs Revenue Share by Application (2018-2023)
Table 48. Global Biogeneric Drugs Price by Application (2018-2023) & (USD/Unit)
Table 49. Sandoz International Corporation Information
Table 50. Sandoz International Description and Business Overview
Table 51. Sandoz International Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 52. Sandoz International Biogeneric Drugs Product
Table 53. Sandoz International Recent Developments/Updates
Table 54. Teva pharmaceutical industries Corporation Information
Table 55. Teva pharmaceutical industries Description and Business Overview
Table 56. Teva pharmaceutical industries Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 57. Teva pharmaceutical industries Biogeneric Drugs Product
Table 58. Teva pharmaceutical industries Recent Developments/Updates
Table 59. Mylan Corporation Information
Table 60. Mylan Description and Business Overview
Table 61. Mylan Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 62. Mylan Biogeneric Drugs Product
Table 63. Mylan Recent Developments/Updates
Table 64. 3SBio Corporation Information
Table 65. 3SBio Description and Business Overview
Table 66. 3SBio Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 67. 3SBio Biogeneric Drugs Product
Table 68. 3SBio Recent Developments/Updates
Table 69. Shanghai Fosun Pharmaceutical Corporation Information
Table 70. Shanghai Fosun Pharmaceutical Description and Business Overview
Table 71. Shanghai Fosun Pharmaceutical Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 72. Shanghai Fosun Pharmaceutical Biogeneric Drugs Product
Table 73. Shanghai Fosun Pharmaceutical Recent Developments/Updates
Table 74. Tonghua Dongbao Pharmaceutical Corporation Information
Table 75. Tonghua Dongbao Pharmaceutical Description and Business Overview
Table 76. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 77. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product
Table 78. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
Table 79. Biocon Corporation Information
Table 80. Biocon Description and Business Overview
Table 81. Biocon Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 82. Biocon Biogeneric Drugs Product
Table 83. Biocon Recent Developments/Updates
Table 84. Reliance life sciences Corporation Information
Table 85. Reliance life sciences Description and Business Overview
Table 86. Reliance life sciences Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 87. Reliance life sciences Biogeneric Drugs Product
Table 88. Reliance life sciences Recent Developments/Updates
Table 89. Probiomed Corporation Information
Table 90. Probiomed Description and Business Overview
Table 91. Probiomed Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 92. Probiomed Biogeneric Drugs Product
Table 93. Probiomed Recent Developments/Updates
Table 94. Biosidus Corporation Information
Table 95. Biosidus Description and Business Overview
Table 96. Biosidus Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 97. Biosidus Biogeneric Drugs Product
Table 98. Biosidus Recent Developments/Updates
Table 99. AMEGA Biotech Corporation Information
Table 100. AMEGA Biotech Description and Business Overview
Table 101. AMEGA Biotech Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 102. AMEGA Biotech Biogeneric Drugs Product
Table 103. AMEGA Biotech Recent Developments/Updates
Table 104. Celltrion Corporation Information
Table 105. Celltrion Description and Business Overview
Table 106. Celltrion Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 107. Celltrion Biogeneric Drugs Product
Table 108. Celltrion Recent Developments/Updates
Table 109. LG life Science Corporation Information
Table 110. LG life Science Description and Business Overview
Table 111. LG life Science Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 112. LG life Science Biogeneric Drugs Product
Table 113. LG life Science Recent Developments/Updates
Table 114. Dong-A Pharmaceutical Corporation Information
Table 115. Dong-A Pharmaceutical Description and Business Overview
Table 116. Dong-A Pharmaceutical Biogeneric Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 117. Dong-A Pharmaceutical Biogeneric Drugs Product
Table 118. Dong-A Pharmaceutical Recent Developments/Updates
Table 119. Production Base and Market Concentration Rate of Raw Material
Table 120. Key Suppliers of Raw Materials
Table 121. Biogeneric Drugs Distributors List
Table 122. Biogeneric Drugs Customers List
Table 123. Biogeneric Drugs Market Trends
Table 124. Biogeneric Drugs Market Drivers
Table 125. Biogeneric Drugs Market Challenges
Table 126. Biogeneric Drugs Market Restraints
Table 127. Global Biogeneric Drugs Sales Forecast by Type (2023-2030) & (K Units)
Table 128. Global Biogeneric Drugs Sales Market Share Forecast by Type (2023-2030)
Table 129. Global Biogeneric Drugs Revenue Forecast by Type (2023-2030) & (US$ Million)
Table 130. Global Biogeneric Drugs Revenue Market Share Forecast by Type (2023-2030)
Table 131. Global Biogeneric Drugs Sales Forecast by Application (2023-2030) & (K Units)
Table 132. Global Biogeneric Drugs Sales Market Share Forecast by Application (2023-2030)
Table 133. Global Biogeneric Drugs Revenue Forecast by Application (2023-2030) & (US$ Million)
Table 134. Global Biogeneric Drugs Revenue Market Share Forecast by Application (2023-2030)
Table 135. Global Biogeneric Drugs Sales Forecast by Region (2023-2030) & (K Units)
Table 136. Global Biogeneric Drugs Sales Market Share Forecast by Region (2023-2030)
Table 137. Global Biogeneric Drugs Revenue Forecast by Region (2023-2030) & (US$ Million)
Table 138. Global Biogeneric Drugs Revenue Market Share Forecast by Region (2023-2030)
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biogeneric Drugs
Figure 2. Global Biogeneric Drugs Market Share by Type in 2022 & 2030
Figure 3. Insulins Product Picture
Figure 4. Growth Hormones Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Biogeneric Drugs Market Share by Application in 2022 & 2030
Figure 8. Hospital
Figure 9. Clinics
Figure 10. Research Centers
Figure 11. Global Biogeneric Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2030
Figure 12. Global Biogeneric Drugs Market Size (2018-2030) & (US$ Million)
Figure 13. Global Biogeneric Drugs Sales (2018-2030) & (K Units)
Figure 14. Biogeneric Drugs Sales Share by Manufacturers in 2022
Figure 15. Global Biogeneric Drugs Revenue Share by Manufacturers in 2022
Figure 16. The Global 5 and 10 Largest Biogeneric Drugs Players: Market Share by Revenue in 2022
Figure 17. Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 18. Global Biogeneric Drugs Sales Market Share by Region (2018-2023)
Figure 19. Global Biogeneric Drugs Sales Market Share by Region in 2022
Figure 20. Global Biogeneric Drugs Revenue Market Share by Region (2018-2023)
Figure 21. Global Biogeneric Drugs Revenue Market Share by Region in 2022
Figure 22. U.S. Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 23. Canada Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 24. Germany Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 25. France Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 26. U.K. Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 27. Italy Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 28. Russia Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 29. China Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 30. Japan Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 31. South Korea Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 32. India Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 33. Australia Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 34. Taiwan Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 35. Indonesia Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 36. Thailand Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 37. Malaysia Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 38. Philippines Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 39. Vietnam Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 40. Mexico Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 41. Brazil Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 42. Argentina Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 43. Turkey Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 44. Saudi Arabia Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 45. U.A.E Biogeneric Drugs Revenue Growth Rate (2018-2023) & (US$ Million)
Figure 46. Sales Market Share of Biogeneric Drugs by Type (2018-2023)
Figure 47. Manufacturing Cost Structure of Biogeneric Drugs
Figure 48. Manufacturing Process Analysis of Biogeneric Drugs
Figure 49. Biogeneric Drugs Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount